SOX9 and Hepatic fibrosis: Loss of SOX9 in vivo alleviates carbon tetrachloride (CCl4) and bile duct ligated (BDL) induced liver fibrosis, including a reduction in collagen deposition and HSC activation, and improved liver functionality [7–9].